The medical community has long possessed the tools to render viral hepatitis a relic of the past. From a vaccine that offers near-total protection against hepatitis B to curative short-course therapies for hepatitis C, the scientific victory was won years ago. Yet, as a physician, the most frustrating aspect of global health is often the gap between what is clinically possible and what is actually delivered to the patient.
A new report from the World Health Organization (WHO), released during the World Hepatitis Summit, underscores this stark disparity. The data reveals a world of contradictions: while global efforts have successfully driven down new hepatitis B infections by 32 percent since 2015, the disease remains a silent killer. In 2024 alone, hepatitis B and C claimed an estimated 1.34 million lives—roughly 3,670 deaths every single day.
The report serves as both a progress marker and a warning. While 85 countries have already met or exceeded the 2030 target for hepatitis B prevalence in children under five, the broader trajectory suggests the world is off track to meet its overall elimination goals. With more than 4,900 new infections occurring daily, the virus continues to outpace the current scale of testing and treatment.
The Paradox of Preventable Death
The tragedy of viral hepatitis is that We see often a “silent” disease. Patients can live for decades without symptoms while the virus slowly destroys the liver, leading to cirrhosis or hepatocellular carcinoma (liver cancer). By the time a patient presents with jaundice or abdominal swelling, the damage is often advanced and irreversible.
This makes the current treatment gaps particularly alarming. Of the 240 million people living with chronic hepatitis B in 2024, fewer than 5 percent were receiving treatment. For hepatitis C, the numbers are slightly better but still insufficient; only 20 percent of those infected have been treated since 2015, the year a breakthrough 12-week curative therapy with a 95 percent success rate became widely available.
“Every missed diagnosis and untreated infection due to chronic viral hepatitis represents a preventable death,” said Dr. Tereza Kasaeva, Director of the WHO Department for HIV, TB, Hepatitis and Sexually Transmitted Infections. The failure to treat is not a failure of medicine, but a failure of delivery—driven by weak health systems, social stigma, and inequitable access to care.
Regional Crisis and the “Birth-Dose” Gap
The burden of the disease is not shared equally. The WHO African Region currently accounts for 68 percent of all new hepatitis B infections. The root of this crisis often begins at birth. Hepatitis B is frequently transmitted from mother to child during delivery, a cycle that can only be broken by a “birth-dose” vaccine administered within 24 hours of birth.
Despite the known efficacy of this intervention, only 17 percent of newborns in the African Region received the birth-dose vaccination in 2024. This gap ensures that a new generation remains vulnerable to chronic infection, which is far more likely to occur when the virus is acquired in infancy.
The report also highlights a concentrated geographic burden of mortality. Ten countries—including India, China, Nigeria, and Viet Nam—accounted for 69 percent of all hepatitis B-related deaths in 2024. Hepatitis C deaths are more widely dispersed, with significant tolls in the United States, Russia, and Pakistan, often linked to the need for better harm reduction services for people who inject drugs, who accounted for 44 percent of new hepatitis C infections.
| Metric (2024 Data) | Hepatitis B | Hepatitis C |
|---|---|---|
| Estimated Chronic Cases | ~240 Million | ~47 Million |
| Treatment Rate | < 5% | ~20% (since 2015) |
| Primary Tool | Vaccine & Long-term Antivirals | Short-course Curative Therapy |
| Estimated Annual Deaths | 1.1 Million | 240,000 |
Blueprints for Success: From Egypt to Rwanda
While the global numbers are sobering, the report highlights that elimination is a tangible reality, not a “pipedream,” as WHO Director-General Dr. Tedros Adhanom Ghebreyesus put it. Several nations have provided a roadmap for others to follow.
Egypt, for example, launched one of the most ambitious hepatitis C elimination campaigns in history, utilizing mass screening and the deployment of direct-acting antivirals to treat millions of citizens. Similarly, Georgia and Rwanda have made significant strides by integrating hepatitis services into primary healthcare, ensuring that testing is not a separate, daunting hurdle for the patient but a routine part of clinical care.
To replicate these successes, the WHO is calling for three priority shifts in global health policy:
- Primary Care Integration: Moving hepatitis screening and treatment out of specialized clinics and into community health centers.
- Enhanced Harm Reduction: Expanding safe injection practices and support services for people who inject drugs to curb the spread of hepatitis C.
- Domestic Financing: Shifting from a reliance on sporadic international aid to sustained, reliable national budgets for liver health.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Please consult a healthcare provider for diagnosis and treatment of viral hepatitis.
The road to 2030 is short, and the current pace of progress is uneven. The next critical checkpoint will be the ongoing monitoring of the 2030 elimination targets, with member states expected to report updated national progress data in the coming year to determine if the necessary scale-up in the African and Western Pacific regions is occurring.
Do you think global health priorities are shifting enough to meet these targets? Share your thoughts in the comments or share this story to raise awareness about liver health.
